A study assessing gene expression in cancer patients revealed both benefit and harm for cancer prognosis from high or low TNF, IL-17A, and IL-23A expression. This conceptual approach may influence future management of dermatologic patients with malignancies .
Biologics like TNF blockers or inhibitors of IL-17A and IL-23 have started a new era of possible achievements in psoriasis treatment. However, there is a worrisome and ongoing discussion about an increased risk of cancer linked to psoriasis management with agents in these drug classes. “Clinicians and dermatologists often face difficult decisions in prescribing these drugs, especially to those who have a history of cancer or those who have a current active cancer,” said Dr Nikolai Klebanov (Brigham and Women’s Hospital, USA).
To gain further insight, a theoretical and hypothesis-generating, observational retrospective study was performed using The Cancer Genome Atlas (TCGA). Over 9,000 patie...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Pembrolizumab leads to higher toxicity risk in obese melanoma patients Next Article
Omalizumab for cancer-induced dermatoses »
Table of Contents: AAD 2020
Psoriasis – What Is Hot?
Systemic Therapies for Dermatologists
Hidradenitis Suppurativa/Acne Inversa
Pearls of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.